All In Biotech

Drug Trial Radar · NCT07770217

A Phase I Clinical Trial to Evaluate Pharmacokinetics of HS-10504

A Phase I Clinical Trial to Evaluate the Effect of Rifampin on the Pharmacokinetics of HS-10504 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Aug 2, 2026

Primary completion

Sep 10, 2026

Study completion Nov 29, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, open-label, fixed-sequence, self-controlled Phase I clinical study with a planned enrollment of approximately 18 healthy participants.

Conditions

  • Healthy Participants

Interventions

  • HS-10504Drug

    Participants will receive a single oral dose of 400 mg HS-10504 tablets on study days D1 and D17, respectively

  • RifampinDrug

    articipants will receive Rifampin capsules 600 mg orally once daily on an empty stomach from Day 10 to Day 24 for 15 consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of CmaxTime frame: 192 hours after administration of HS-10504
  2. Evaluation of AUC0-tTime frame: 192 hours after administration of HS-10504
  3. Evaluation of AUC0-∞Time frame: 192 hours after administration of HS-10504

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.